Phase Ib Open-label Study of VAY736 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2018
At a glance
- Drugs Ianalumab (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 18 Jun 2018 Planned End Date changed from 5 Sep 2019 to 21 Oct 2019.
- 18 Jun 2018 Planned primary completion date changed from 5 Sep 2019 to 21 Oct 2019.
- 18 Jun 2018 Status changed from not yet recruiting to recruiting.